TORAFIC study protocol: Torasemide prolonged release versus furosemide in patients with chronic heart failure

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 8, 2009, Pages 897-904

  Díez, Javier ^a   Coca, Antonio ^b   De Teresa, Eduardo ^c   Anguita, Manuel ^d   Castro Beiras, Alfonso ^e   Conthe, Pedro ^f   Cobo, Erik ^g   Fernández, Ester ^h  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital Clinico de Malaga   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g Department of Statistics and Operational Research   (Spain)

^h I3 Research   (Spain)

Author keywords

Chronic heart failure; Furosemide; Myocardial fibrosis; Torasemide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; PROCOLLAGEN C PROTEINASE; TORASEMIDE; COLLAGEN TYPE 1; DIURETIC AGENT; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; SULFONAMIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART RATE; HUMAN; KIDNEY FUNCTION; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY URGENCY; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; FEMALE; FIBROSIS; MALE; METHODOLOGY; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

CHRONIC DISEASE; COLLAGEN TYPE I; DELAYED-ACTION PREPARATIONS; DIURETICS; FEMALE; FIBROSIS; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; RESEARCH DESIGN; SULFONAMIDES;

EID: 70350455301     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.74     Document Type: Article

References (38)

1. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur. Heart J. 20, 447-455 (1999). (Pubitemid 29116541)
2. Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E et al; PRICE study investigators. Prevalence of heart failure in the Spanish general population aged over 45 years. Rev. Esp. Cardiol. 61, 1041-1049 (2008).
3. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med. 285, 1441-1446 (1971).
4. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur. Heart J. 1, 229-241 (1999). (Pubitemid 30129391)
5. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur. Heart J. 22, 623-626 (2001). (Pubitemid 32622421)
6. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849 (2005).
7. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol. Clin. 18, 435-442 (2000).
8. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am. J. Physiol. Heart Circ. Physiol. 286, H1-H10 (2004).
9. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27, 92-98 (2002).
10. Brower GL, Gardner JD, Forman MF et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothorac. Surg. 30, 604-610 (2006).
11. Díez J, González A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat. Clin. Pract. Cardiovasc. Med. 2, 209-216 (2005). (Pubitemid 40812484)
12. Querejeta R, Varo N, López B et al. Serum carboxy-terminal propeptide procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101, 1729-1735 (2000). (Pubitemid 30196635)
13. Querejeta R, López B, González A et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110, 1263-1268 (2004). (Pubitemid 39202343)
14. López B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104, 286-291 (2001). (Pubitemid 32666949)
15. González A, López B, Ravassa S et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc. Res. 81, 509-518 (2009).
16. Swedberg K, Cleland J, Dargie H et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26, 1115-1140 (2005).
17. Hunt SA, Abraham WT, Chin MH et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112, E154-E235 (2005).
18. Ishido H, Senzaki H. Torasemide for the treatment of heart failure. Cardiovasc. Hematol. Disord. Drug Targets 8, 127-132 (2008).
19. Cosín J, Díez J; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 4, 507-513 (2002). (Pubitemid 36564972)
20. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 49, 121-142 (1995).
21. Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet. 34, 1-24 (1998).
22. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur. J. Clin. Pharmacol. 31, 21-27 (1986).
23. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. 57, 601-609 (1995).
24. Barbanoj MJ, Ballester MR, Antonijoan RM et al. A bioavailability/ bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 mg and 10 mg): prolonged-release versus the conventional formulation. Clin. Exp. Pharmacol. Physiol. 36(5-6), 469-477 (2008) .
25. Gropper S, Rojas MJ, Guglietta A et al. Single and repeated-dose, randomized, cross-over, bioavailability clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide. Basic Clin. Pharmacol. Toxicol. 99(Suppl. 1), 48 (2006) (Abstract).
26. Sutril Neo (torasemide prolonged release), summary of product characteristics. Ferrer Grupo, Barcelona, Spain (2006).
27. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gómez C et al.; the Torasemide-PR in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in milt to moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc. Ther. 26, 91-100 (2008).
28. Veeraveedu PT, Watanabe K, Ma M et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 75, 649-659 (2008).
29. Veeraveedu PT, Watanabe K, Ma M et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur. J. Pharmacol. 581, 121-131 (2008).
30. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 43, 2028-2035 (2004). (Pubitemid 38686797)
31. López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 859-867 (2007). (Pubitemid 47268745)
32. López B, Querejeta R, González A, Beaumont J, Larman M, Díez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 53(2), 236-242 (2009).
33. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am. Heart J. 124, 1017-1025 (1992).
34. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1, 113-119 (1992).
35. Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement of the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 28, 2539-2550 (2007). (Pubitemid 47614269)
36. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
37. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther. 21, 247-254 (1977). (Pubitemid 8064243)
38. González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr. Opin. Nephrol. Hypertens. 14, 428-434 (2005). (Pubitemid 41152704)